IUC26669-94

Abstract Code: IUC26669-94   The LDR BURST Trial: A Randomised Comparison of Toxicity Outcomes following LDR Brachytherapy vs 5-Fraction SBRT with a Rectal Spacer for Localised Prostate Cancer W. Hayhurst 1, S. Uribe-Lewis 2, J. Uribe 2, C. Mikropoulos 2, S....

IUC26667-92

Abstract Code: IUC26667-92   Assessment of QRISK®3 and Major Cardiovascular Events in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with ADT ± ARPI ± Docetaxel: A Retrospective Cohort Study T. Alom 1, A. Kutty 1, G. Neola 1, L. Pedapati 1, A....

IUC26665-90

Abstract Code: IUC26665-90   Global inequalities in prostate cancer incidence and mortality: an ecological analysis M.S. Hosseini 1, Y. Vaez-Gharamaleki 1, A. Motamedi 1 (1) Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz...

IUC26663-88

Abstract Code: IUC26663-88   Real-world ARASENS triplet therapy in high-volume mHSPC: a single-centre cohort M.P. Juan Gonzalez 1, C. Martinez Martinez 1, A.J. Montalban Valverde 1, P.A. Barranzuela Decoll 1, Y. El Farh Boumajdil 1, E.J. Soria Hernandez 1, B....

IUC26662-87

Abstract Code: IUC26662-87   Ultra-low PSA as a real-world indicator of androgen receptor pathway inhibitors (ARPI) treatment response in metastatic prostate cancer M. Ghigeanu 1, I. Bogatu 2, M.A. Barbu 3 (1) Bucharest Institute of Oncology – Romania, (2)...

IUC26661-86

Abstract Code: IUC26661-86   Real-world outcomes in patients with Metastatic Hormone-Sensitive Prostate Cancer treated with androgen deprivation therapy and Apalutamide – A single centre study K. Marchon 1, S. Brown 1, K. Swaminathan 1, S. Adeyemi 1, G....
error: Content is protected !!